Relevant articles and documents
All total 3 Articles be found
All total 3 Articles be foundThe Use of Crown Ethers in Peptide Chemistry IV. Solid Phase Synthesis of Peptides Using Peptide Fragments Nα Protected With 18-Crown-6
Botti, Paolo,Ball, Haydn L.,Rizzi, Emanuele,Lucietto, Pierluigi,Pinori, Massimo,Mascagni, Paolo
, p. 5447 - 5458 (2007/10/02)
The conditions under which peptide synthesis by the fragment condensation approach in the solid phase can be carried out using crown ethers as non-covalent protecting groups for the Nα amino group of peptides were determined.The dipeptide Gly-Gly was complexed with 18-crown-6 to establish the feasibility of this new protection scheme and to optimise the reaction conditions.Nearly quantitative incorporation of the complex onto resin-bound amino acids possessing either proline or an Nα-alkylated amino acids was achieved using DCM as the activation and coupling reactions solvent.The use of DMF as the solvent and resin-bound primary amino acids were found detrimental to the reaction yields due to the removal of the crown ether protection.Extending the length of the peptide fragment to model pentapeptide complexes bearing no reactive functionalities on the side-chain gave essentially quantitative incorporation yields in the coupling reactions to both resin-bound amino acids and short peptides.The non-covalent nature of the protection afforded by the crown molecule allowed its mild removal from resin-bound complexes by rapid treatments with 1percent DIEA solutions.Thus the continuation of chain assembly was possible.The results obtained served as the basis for extending the concept of non-covalent protection to the side chains of Lys and Arg containing peptides.
Medicament which antagonizes the action of gastrin and related polypeptides
-
, (2008/06/13)
The present invention relates to a method of treating diseases and particularly gastroduodenal ulcers linked to an hypersecretion of gastrin, and to polypeptide amide derivatives which can be used in this method as therapeutic agents and more specifically as antagonists of the action of gastrin and related polypeptides relative to their specific biological receptors. This method comprises administering a therapeutically effective amount of a polypeptide amide derivative of general formula: STR1 in which R1 represents a hydrogen atom or an acyl radical and R2 represents a substituted or unsubstituted aryl radical e.g. nitrophenyl group or dinitrophenyl group such as 2-nitrophenyl or 2-4-dinitrophenyl.
